Celgene

CELG

Delayed Nasdaq Other stock markets 04:00:00 2019-11-20 pm EST			5-day change	1st Jan Change
108.2 ^USD	+0.10%		-1.97%	+68.89%

2023	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
2021	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

Celgene Corporation's Equity Buyback announced on June 12, 2013, has expired.

November 19, 2019

The company expired its plan on November 20, 2019, on account of its acquisition by Bristol-Myers Squibb Company (NYSE:BMY).

Latest news about Celgene

Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	23-06-14	CI
Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	21-09-07	CI
Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	21-06-21	CI
Celgene Corporation Issues Notice of Redemption of Notes	21-02-22	CI
Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	21-02-04	CI
Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	21-01-04	CI
Amgen : Signs Licensing Agreement With Medicines Development for Global Health	20-12-22	MT
Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	20-11-05	MT
Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	20-09-22	CI
Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	20-09-21	CI
Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	20-03-25	CI
Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	20-03-10	CI
Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	20-03-04	CI
DISH Network : Democratic lawmaker presses antitrust enforcers on company ties, settlements	20-01-07	RE
Galecto, Inc. acquired PharmAkea, Inc. from Bay City Capital LLC and Celgene Corporation for $17.4 million	20-01-06	CI
GNS Healthcare, Inc. announced that it has received $28 million in funding from Cigna Ventures, Amgen Ventures, Celgene Corporation, Echo Health Ventures, Alexandria Venture Investments, LLC, Merck Global Health Innovation Fund, LLC, and another investor	20-01-06	CI
More drugmakers hike U.S. prices as new year begins	20-01-01	RE
Dealmakers eye cross-border M&A recovery as mega mergers roll on	19-12-31	RE
Oncorus, Inc. announced that it has received $89.6 million in funding from a group of investors	19-12-19	CI
Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug	19-11-21	RE
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Growth	19-11-21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P TMI Index	19-11-21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from INDUSTRIALS	19-11-21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Value	19-11-21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P Global 1200	19-11-21	CI

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Sector

More about the company

Celgene

Equities

CELG

Celgene Corporation's Equity Buyback announced on June 12, 2013, has expired.

Latest news about Celgene

Chart Celgene

Company Profile